Search Results

As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. announced recent FDA approval of a lower profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.

W. L. Gore & Associates (Gore) announced the first patient implantation of the GORE® Ascending Stent Graft in the ARISE II Trial, an exciting step in the development of treatments for pathologies involving the ascending aorta using endovascular repair rather than traditional open surgery.

W. L. Gore & Associates, Inc. (“Gore”), a global materials science company, continues to build on its growing portfolio of protein capture devices with the introduction of its 250mL, 500mL and 1L GORE® Protein Capture Devices with Protein A.

W. L. Gore & Associates announced the initiation of the Gore VBX FORWARD Clinical Study to compare the VBX Stent Graft to bare metal stenting for patients with complex iliac occlusive disease.

W. L. Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, non-randomized, multicenter, single-arm study with five-year follow-up (NCT05489588) to evaluate the investigational GORE® VIAFORT Vascular Stent for the treatment of symptomatic iliofemoral venous obstruction.

Arzeda, the industry-leading Protein Design Company™, announced today that it is collaborating with W. L. Gore & Associates, a global leader in advanced materials science, on research leveraging Arzeda’s technology platform that economically and efficiently creates new and enhances existing proteins.

W. L. Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, non-randomized, multicenter, single-arm study with 5-year follow-up (NCT05409976) to evaluate the investigational GORE® VIAFORT Vascular Stent for the Treatment of Symptomatic Inferior Vena Cava (IVC) Obstruction with or without combined Iliofemoral Obstruction.

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a diversified supply chain, executives said during the company’s Q1 investor call.